Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 11/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647886 | 0.88 | MMP7 (0.41) | MMP7DRD3DRD2CYP3A4MMP13 | |
| SCHEMBL6670937 | 0.82 | MMP7 (0.62) | MMP7DRD3DRD2CYP3A4MMP13 | |
| SCHEMBL3943167 | 0.79 | CYP3A4 (0.43) | MMP7CYP3A4MMP13CTSSTP53 | |
| SCHEMBL6807027 | 0.78 | MMP7 (0.53) | MMP7CYP3A4MMP13CTSS | |
| SCHEMBL6806277 | 0.76 | MMP7 (0.52) | MMP7CYP3A4MMP13CTSS | |
| SCHEMBL6644515 | 0.76 | MMP7 (0.46) | MMP7CYP3A4MMP13CTSS | |
| SCHEMBL6811849 | 0.74 | DRD3 (0.36) | DRD3DRD2MAPKAPK2 | |
| SCHEMBL6646411 | 0.74 | DRD3 (0.36) | DRD3DRD2MAPKAPK2 | |
| SCHEMBL5883424 | 0.74 | MMP7 (0.53) | MMP7CYP3A4MMP13CTSSTP53 | |
| SCHEMBL6643456 | 0.73 | DRD3 (0.35) | MMP7DRD3DRD2CYP3A4MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | US | claimed |
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | US | disclosed |
| EP-1417181-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003014092-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | MMP7 18/4885DRD3 2441/4885DRD2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.